

U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027

<https://marketpublishers.com/r/U16A89F22EFDEN.html>

Date: January 2021

Pages: 153

Price: US\$ 2,599.00 (Single User License)

ID: U16A89F22EFDEN

Abstracts

The U.S. pain management drugs market was valued at \$31,499.07 million in 2019, and is projected to reach \$39,356.45 million by 2027, registering a CAGR of 3.4%.

Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the U.S. pain management drugs market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth. The U.S. pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.

On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. On the basis of pain type, the market is segmented into chronic and acute pain.

The key players operating in the U.S. pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current U.S. pain management drugs market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.

The market forecast is studied from 2020 to 2027.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Drug Class

NSAIDS

Anesthetics

Anticonvulsants

Antimigraine Agents

Antidepressants

Opioids

Nonnarcotic Analgesics

By Indication

Arthritic Pain

Neuropathic Pain

Cancer Pain

Chronic Back Pain

Postoperative Pain

Migraine

Fibromyalgia

Bone fracture

Muscle sprain/strain

Acute appendicitis

Others

By Pain type

Chronic pain

Acute pain

Contents

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
- 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
 - 3.2.2.Top winning strategies
- 3.3.Top player positioning
- 3.4.Porter's five force analysis
- 3.5.Market dynamics
 - 3.5.1.Drivers
 - 3.5.1.1.Rise in incidences of chronic diseases
 - 3.5.1.2.Favorable regulatory scenario
 - 3.5.1.3.Increase in geriatric population
 - 3.5.2.Restraints
 - 3.5.2.1.Availability of alternative therapies
 - 3.5.2.2.Drug exploitation
 - 3.5.2.3.Patent expiration of prescription drugs
 - 3.5.3.Opportunity
 - 3.5.3.1.Advancements in drug development
 - 3.5.4.Impact Analysis
- 3.6.COVID-19 impact analysis for U.S. Pain Management Drugs

CHAPTER 4:U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast

4.4.Anticonvulsants

4.4.1.Key market trends, growth factors, and opportunities

4.4.2.Market size and forecast

4.5.Antimigraine drug

4.5.1.Key market trends, growth factors, and opportunities

4.5.2.Market size and forecast

4.6.Antidepressants

4.6.1.Key market trends, growth factors, and opportunities

4.6.2.Market size and forecast

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities

4.7.2.Market size and forecast

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities

4.8.2.Market size and forecast

CHAPTER 5:U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic pain

5.2.1.Market size and forecast

5.3.Neuropathic pain

5.3.1.Market size and forecast

5.4.Cancer pain

5.4.1.Market size and forecast

5.5.Chronic back pain

5.5.1.Market size and forecast

5.6.Post-operative pain

- 5.6.1. Market size and forecast
- 5.7. Migraine
 - 5.7.1. Market size and forecast
- 5.8. Fibromyalgia
 - 5.8.1. Market size and forecast
- 5.9. Bone fracture
 - 5.9.1. Market size and forecast
- 5.10. Muscle sprain/strain
 - 5.10.1. Market size and forecast
- 5.11. Acute appendicitis
 - 5.11.1. Market size and forecast
- 5.12. Others
 - 5.12.1. Market size and forecast

CHAPTER 6: PAIN MANAGEMENT DRUGS, BY PAIN TYPE

- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. Chronic pain
 - 6.2.1. Market size and forecast
- 6.3. Acute pain
 - 6.3.1. Market size and forecast

CHAPTER 7: COMPANY PROFILES

- 7.1. ABBOTT LABORATORIES
 - 7.1.1. Company overview
 - 7.1.2. Company snapshot
 - 7.1.3. Operating business segments
 - 7.1.4. Product portfolio
 - 7.1.5. Business performance
- 7.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 - 7.2.1. Company overview
 - 7.2.2. Company snapshot
 - 7.2.3. Operating business segments
 - 7.2.4. Product portfolio
 - 7.2.5. Business performance
- 7.3. ELI LILY AND COMPANY
 - 7.3.1. Company overview

- 7.3.2. Company snapshot
- 7.3.3. Operating business segments
- 7.3.4. Product portfolio
- 7.3.5. Business performance
- 7.3.6. Key strategic moves and developments
- 7.4. GLAXOSMITHKLINE PLC (GSK)
 - 7.4.1. Company overview
 - 7.4.2. Company snapshot
 - 7.4.3. Operating business segments
 - 7.4.4. Product portfolio
 - 7.4.5. Business performance.
 - 7.4.6. Key strategic moves and developments
- 7.5. JOHNSON & JOHNSON
 - 7.5.1. Company overview
 - 7.5.2. Company snapshot
 - 7.5.3. Operating business segments
 - 7.5.4. Product portfolio
 - 7.5.5. Business performance
- 7.6. MERCK & CO., INC.
 - 7.6.1. Company overview
 - 7.6.2. Company snapshot
 - 7.6.3. Operating business segments
 - 7.6.4. Product portfolio
 - 7.6.5. Business performance
 - 7.6.6. Key strategic moves and developments
- 7.7. MYLAN N.V.
 - 7.7.1. Company overview
 - 7.7.2. Company snapshot
 - 7.7.3. Operating business segments
 - 7.7.4. Product portfolio
 - 7.7.5. Business performance
 - 7.7.6. Key strategic moves and developments
- 7.8. NOVARTIS INTERNATIONAL AG
 - 7.8.1. Company overview
 - 7.8.2. Company snapshot
 - 7.8.3. Operating business segments
 - 7.8.4. Product portfolio
 - 7.8.5. Business performance
 - 7.8.6. Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview

7.9.2.Company snapshot

7.9.3.Operating business segments

7.9.4.Product portfolio

7.9.5.Business performance

7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview

7.10.2.Company snapshot

7.10.3.Operating business segments

7.10.4.Product portfolio

7.10.5.Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027
(\$MILLION)

TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027
(\$MILLION)

TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027
(\$MILLION)

TABLE 04.ABBOTT: COMPANY SNAPSHOT

TABLE 05.ABBOTT: OERATING SEGMENT

TABLE 06.ABBOTT: PRODUCT PORTFOLIO

TABLE 07.BOEHRINGER INGELHEIM : COMPANY SNAPSHOT

TABLE 08.BOEHRINGER INGELHEIM : OPERATING SEGMENTS

TABLE 09.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO

TABLE 10.ELI LILLY: COMPANY SNAPSHOT

TABLE 11.LILLY: OPERATING SEGMENTS

TABLE 12.ELI LILLY: PRODUCT PORTFOLIO

TABLE 13.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 14.GSK: COMPANY SNAPSHOT

TABLE 15.GSK: OPERATING SEGMENTS

TABLE 16.GSK: PRODUCT PORTFOLIO

TABLE 17.J&J: COMPANY SNAPSHOT

TABLE 18.J&J: OPERATING BUSINESS SEGMENTS

TABLE 19.J&J: PRODUCT PORTFOLIO

TABLE 20.MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 21.MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 22.MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 23.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 24.MYLAN: COMPANY SNAPSHOT

TABLE 25.MYLAN: OPERATING BUSINESS SEGMENTS

TABLE 26.MYLAN: PRODUCT PORTFOLIO

TABLE 27.NOVARTIS: COMPANY SNAPSHOT

TABLE 28.NOVARTIS: OPERATING SEGMENTS

TABLE 29.NOVARTIS: PRODUCT PORTFOLIO

TABLE 30.PFIZER: COMPANY SNAPSHOT

TABLE 31.PFIZER: OERATING SEGMENT

TABLE 32.PFIZER: PRODUCT PORTFOLIO

TABLE 33.PURDUE: COMPANY SNAPSHOT
TABLE 34.PURDUE: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION

FIGURE 02.TOP INVESTMENT POCKETS

FIGURE 03.TOP WINNING STRATEGIES, 2017–2020

FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020

FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020

FIGURE 06.TOP PLAYER POSITIONING, 2019

FIGURE 07.MODERATE BARGAINING POWER OF BUYERS

FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 09.MODERATE THREAT OF SUBSTITUTES

FIGURE 10.MODEARTE THREAT OF NEW ENTRANTS

FIGURE 11.MODERATE COMPETITIVE OF RIVALRY

FIGURE 12.IMPACT ANALYSIS, U.S. PAIN MANAGEMENT DRUGS MARKET

FIGURE 13.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2019-2027
(\$MILLION)

FIGURE 14.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC,
2019-2027 (\$MILLION)

FIGURE 15.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS,
2019-2027 (\$MILLION)

FIGURE 16.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE
AGENTS, 2019-2027 (\$MILLION)

FIGURE 17.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS,
2019-2027 (\$MILLION)

FIGURE 18.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2019-2027
(\$MILLION)

FIGURE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC
ANALGESICS, 2019-2027 (\$MILLION)

FIGURE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY,
2019-2027 (\$MILLION)

FIGURE 21.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN,
2019-2027 (\$MILLION)

FIGURE 22.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN,
2019-2027 (\$MILLION)

FIGURE 23.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK
PAIN, 2019-2027 (\$MILLION)

FIGURE 24.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE

PAIN, 2019-2027 (\$MILLION)

FIGURE 25.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2019-2027 (\$MILLION)

FIGURE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2019-2027 (\$MILLION)

FIGURE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2019-2027 (\$MILLION)

FIGURE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2019-2027 (\$MILLION)

FIGURE 29.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2019-2027 (\$MILLION)

FIGURE 30.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2019-2027 (\$MILLION)

FIGURE 31.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2019-2027 (\$MILLION)

FIGURE 32.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2019-2027 (\$MILLION)

FIGURE 33.ABBOTT: NET SALES, 2017–2019 (\$MILLION)

FIGURE 34.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 35.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 36.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 (\$MILLION)

FIGURE 37.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 38.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 39.ELI LILLY: NET SALES, 2017–2019 (\$MILLION)

FIGURE 40.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 41.GSK: NET SALES, 2017–2019 (\$MILLION)

FIGURE 42.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 43.GSK: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 44.J&J: NET SALES, 2017–2019 (\$MILLION)

FIGURE 45.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 46.J&J: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 47.MERCK & CO., INC.: NET SALES, 2017–2019 (\$MILLION)

FIGURE 48.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 49.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 50.MYLAN: NET SALES, 2017–2019 (\$MILLION)

FIGURE 51.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 52.NOVARTIS: NET SALES, 2017–2019 (\$MILLION)

FIGURE 53.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 54.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 55.PFIZER: NET SALES, 2017–2019 (\$MILLION)

FIGURE 56.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 57.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

I would like to order

Product name: U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027

Product link: <https://marketpublishers.com/r/U16A89F22EFDEN.html>

Price: US\$ 2,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U16A89F22EFDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970